Immediate and Medium-Term Results of Aortic Valve Replacement With Biological Prosthesis in Elderly Patients: One Center’s Experience
Authors:
- Bakytbek KadyralievBKBakytbek Kadyraliev
- Vyacheslav BelovVBVyacheslav Belov
- Andrey MarchenkoAMAndrey Marchenko
- Vagram ArutunyanVAVagram Arutunyan
- Soslan EngioevSoslan Engioev
- Konstantin ZhigalovKZKonstantin Zhigalov
- Orhan MusaevOMOrhan Musaev
- Nurslu KdralievaNKNurslu Kdralieva
- Alex G. KuchumovAlex G. Kuchumov
Preprint
- 18 May 2023
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Currently, aortic valve (AV) disease is the most common reason for heart valve surgery. The gold standard of care for people with aortic pathology is thought to be AV replacement. The issue of prosthesis selection has always been important. Although mechanical prosthesis are robust, lifelong anticoagulation medication is necessary due to the significant risk of thromboembolic consequences. Biological prostheses have a flow structure that is similar to the physiological one, and as malfunction gradually sets in, scheduled recurrent surgery can be carried out. The purpose of this study is to evaluate the short- and long-term effects of biological prosthetic aortic valve replacement (AVR) in elderly individuals. The study included 198 patients with AV pathology [85 men (42.9%)/113 women (57.1%)]. The median age was 70 [66–73] years. There were 175 (88.4%) patients with degenerative AV, 5 (2.5%) with infective endocarditis, and 30 patients (15.2%) had bicuspid AV. The median follow-up period was 26.3±1.4 months. Hospital mortality was 4.5%. No wound complications were detected. Thirty-one patients died in the long-term period. The causes of lethality were: cardiovascular disease (13 patients), malignant neoplasm (5 patients), gastrointestinal disease (2 patients), urinary system disease (1 patient), COVID-19 (1 patient), unknown cause (9 patients). Thus, the five-year postoperative survival rate was 63%, respectively. Throughout the observation period, two patients (2.9%) underwent reoperation on AV. 97.1% of patients were free of reoperation after five years. The five-year survival rate was 63% due to the history of severe concomitant pathology and mean age of the patients of 70 years.Keywords
All Related Versions
- Version 1, 2023-05-18, Preprints
- Published version: Perm Medical Journal, 40 (6), 61.
This publication has 17 references indexed in Scilit:
- Long-term outcomes of mechanical versus biological aortic valve prosthesis: Systematic review and meta-analysisThe Journal of Thoracic and Cardiovascular Surgery, 2019
- Selection of prosthetic aortic valve and root replacement in patients younger than age 30 yearsThe Journal of Thoracic and Cardiovascular Surgery, 2019
- Bioprosthetic aortic valve replacement: Revisiting prosthesis choice in patients younger than 50 years oldThe Journal of Thoracic and Cardiovascular Surgery, 2018
- Aortic valve reconstruction using autologous pericardium (Ozaki procedure) for active infective endocarditis: a case reportGeneral Thoracic and Cardiovascular Surgery, 2017
- Long-Term Durability of Bioprosthetic Aortic Valves: Implications From 12,569 ImplantsThe Annals of Thoracic Surgery, 2015
- Very Long-Term Outcomes of the Carpentier-Edwards Perimount Valve in Aortic PositionThe Annals of Thoracic Surgery, 2015
- Aortic valve prosthesis selection in dialysis patients based on the patient’s conditionJournal of Artificial Organs, 2012
- Risk-corrected impact of mechanical versus bioprosthetic valves on long-term mortality after aortic valve replacementThe Journal of Thoracic and Cardiovascular Surgery, 2006
- Long-term outcomes of valve replacement with modern prostheses in young adultsEuropean Journal of Cardio-Thoracic Surgery, 2005
- A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley studyThe American Journal of Medicine, 2002